Alnylam Rises 0.87% on $430M Volume Climbs to 244th in US Turnover

On September 24, 2025, Alnylam Pharmaceuticals (ALNY) closed with a 0.87% gain, trading on $430 million in volume, ranking 244th in U.S. stock market turnover for the session. The biotech stock saw strong relative performance amid mixed broader market conditions.

Recent regulatory developments have positioned Alnylam as a key player in RNA therapeutics innovation. The company's pipeline advancements in gene-silencing therapies continue to attract institutional attention, with analysts highlighting its first-mover advantage in the oligonucleotide drug delivery space. Strategic collaborations with major pharmaceutical partners remain central to its growth trajectory.

Market participants are closely monitoring upcoming data readouts from late-stage trials, which could validate Alnylam's therapeutic approach across multiple disease indications. The stock's volume profile suggests increased positioning activity as key catalysts approach, though short-term volatility remains a factor given the sector's sensitivity to clinical developments.

To set up an accurate back-test I need to pin down a few practical details about how the strategy should be executed: 1. Market universe • Should I restrict the universe to U.S. common stocks (NASDAQ + NYSE), or do you want a broader / different list? 2. Signal construction • Do we rank stocks on the day’s total share volume measured at the close? • Are the top-500 names re-balanced every trading day (i.e., we form a new list each day)? 3. Trade execution assumptions • Entry price: next day’s open, or the same day’s close? • Exit price (after one-day hold): same day’s close (if entry at open) / next day’s close (if entry at previous close)? • Any per-trade transaction cost or commission to include? 4. Weighting method • Equal-weight each of the 500 names, or value-weight by market-cap, or some other approach? Once I have these details I can generate the daily trading signals, run the back-test from 2022-01-03 to the present, and return the performance report.